



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

3<sup>rd</sup> April 2023

IOLCP/CGC/2023

**National Stock Exchange of India Ltd**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**Security Symbol: IOLCP**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

**Security Code: 524164**

**Subject: Outcome of the Board Meeting dated 3<sup>rd</sup> April 2023**

Dear Sir,

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 3<sup>rd</sup> April 2023 has inter alia has:

1. Approved the change of the designation of Mr Vikas Gupta from Executive Director to Joint Managing Director of the Company.
2. Appointed Mr Abhiraj Gupta as Additional Director in the category of Executive Director with effect from 3<sup>rd</sup> April 2023.
3. Appointed Mr Vikas Vij as Chief Executive Officer (CEO) of the Company with effect from 3<sup>rd</sup> April 2023.
4. Took note of the resignation of Dr Sanjay Chaturvedi (DIN: 08927689) from the position of Executive Director & CEO of the Company and accorded their approval to relieve Dr. Sanjay Chaturvedi from the closure of business hours on 3<sup>rd</sup> April 2023.

The Board placed on record its appreciation for the contribution made by Dr. Sanjay Chaturvedi during his tenure with the Company.

5. Took note of the completion of Unit 9, a multi-product manufacturing facility at Barnala Plant site.

The details as per SEBI Circular CIR/CFD/CMD/4/2015 dated 09.09.2015 are enclosed herewith as **Annexure 1**.

Mr Vikas Gupta and Mr Abhiraj Gupta are not debarred from holding the office of director by virtue of any order of SEBI or any other such authority.

The meeting was commenced at 3:30 PM and concluded at 5:45 PM.

Thanking You,  
Yours faithfully,  
For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh  
Vice President & Company Secretary



The details as per SEBI Circular CIR/CFD/CMD/4/2015 dated 09.09.2015 are as under:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Mr Vikas Gupta</b>	<b>Mr Abhiraj Gupta</b>	<b>Mr Vikas Vij</b>	<b>Dr Sanjay Chaturvedi</b>
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Change in Designation	Appointment	Appointment	Resignation
2.	Date of appointment / resignation	3 <sup>rd</sup> April 2023	3 <sup>rd</sup> April 2023	3 <sup>rd</sup> April 2023	3 <sup>rd</sup> April 2023
3.	Term of appointment;	Subject to the approval by the Shareholders the Board changed the designation of Mr. Vikas Gupta, Executive Director to the Joint Managing Director of the Company for the remaining period of his existing term i.e. till 28 <sup>th</sup> May 2025	Term: For a period of 5 years effective from April 03 <sup>rd</sup> 2023 subject to the approval of Shareholders of the Company.	Mr Vikas Vij appointed as Chief Executive Officer of the Company w.e.f 3 <sup>rd</sup> April 2023	N.A
4.	Brief profile (in case of appointment);	As given below	As given below	As given below	N.A.
5.	Disclosure of relationships between directors (in case of appointment of a director).	Mr Vikas Gupta is son of Mr Varinder Gupta, Managing Director and brother of Mr Abhiraj Gupta.	Mr Abhiraj Gupta is son of Mr Varinder Gupta, Managing Director and brother of Mr Vikas Gupta, Executive Director	No	N.A.

### **Mr Vikas Gupta – Brief Profile**

Mr. Vikas Gupta graduated from King’s College London, University of London, with a Bachelor of Science in Business Management. He is intellectually prepared and has organizational abilities. Over the previous 10 years, he has been critical to the organization’s operations, marketing, and strategy where he was instrumental in developing the Company’s businesses. Vikas plays a significant role in guiding the Company’s chemical and pharmaceutical business. He is associated with the company for last 10 years.

### **Mr Abhiraj Gupta – Brief Profile**

Mr Abhiraj Gupta, Bachelor of Science in Management and Engineering in Business Management from University of Warwick, U.K. is associated with the Company since September 2017. He possesses the



## **IOL CHEMICALS AND PHARMACEUTICALS LIMITED**

requisite qualifications and experience related to the business of the Company and at present he is responsible for non-ibuprofen API and chemical business, R&D, regulatory and digital marketing of the Company. Under his leadership the non-ibuprofen API business is performing well.

### **Mr Vikas Vij – Brief Profile**

Mr. Vikas Vij joined IOL today as its 'Chief Executive Officer. Vikas has had a dynamic career spanning over 30 years reflecting pioneering experience and year-on-year success in achieving revenue, profitability and business growth objectives in start-up and established organizations.

Vikas has a Techno-commercial background with deep understanding of API and Chemical Industry and operations across Manufacturing, R&D, Procurement, SCM, RA & QA. He has a comprehensive knowledge of critical business drivers in both advanced and emerging markets.

Vikas has handled various leadership roles across Pharma value chain such as Active Pharmaceutical Ingredients (APIs), Finished Dosage Form (FDF), Custom Pharmaceutical Services (CRAMS), Specialty Chemicals, and achieved multi- million Dollar sales targets.

He joins us from Cipla where he was leading the API and Access Business Units. His earlier stints have been with Sun Pharma and Ranbaxy.

We believe that his skills and experience will bring growth across domestic and international markets, portfolio enhancement, efficiencies and professionalism to IOL making it one of the leading player in its' segment.